This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of Imipramine for Treatment of Patients With Esophageal Hypersensitivity/ Functional Heartburn

This study has been completed.
Information provided by (Responsible Party):
Mahidol University Identifier:
First received: December 17, 2012
Last updated: August 15, 2014
Last verified: August 2014

Esophageal hypersensitivity/Functional heartburn are common among non-erosive reflux disease (NERD) patients who do not response to proton pump inhibitors. Whether tricyclic antidepressant improves NERD patient's symptoms remains unknown

Aim of this randomized controlled trial study is to determine the efficacy of imipramine, which could increase esophageal pain thresholds in healthy volunteers, in comparison with placebo for treatment patients with esophageal hypersensitivity or functional heartburn evaluated by improvement of specific-symptom score and quality of life

Condition Intervention Phase
Gastroesophageal Reflux Disease Drug: imipramine Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy of Imipramine for Treatment of Patients With Esophageal

Resource links provided by NLM:

Further study details as provided by Mahidol University:

Primary Outcome Measures:
  • improvement of GERD score [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • improve quality of life [ Time Frame: 6 months ]

Enrollment: 83
Study Start Date: December 2012
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: imipramine Drug: imipramine


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patient with typical reflux symptoms (heartburn and/or regurgitation) more than 3 times per week in at least last 3 months
  • Age more than 18 years
  • Upper GI endoscopy showed no esophageal mucosal breaks
  • MII-pH monitoring was not showed abnormal both acid and non-acid reflux
  • symptoms was not improved after received standard dose proton pump inhibitor for at least 1 month

Exclusion Criteria:

  • history of thoracic, esophagus, or stomach surgery
  • severe esophageal motility disorder eg. Achalasia, scleroderma, autonomic/peripheral neuropathy/myopathy
  • patient who was indicated to receive proton pump inhibitor
  • pregnant women
  • patient who was allergy to imipramine
  • patient who received tricyclic antidepressant or SSRI with in 3 month of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01753128

Medical Institue; Siriraj Hospital
Bangkok, Thailand, 10700
Sponsors and Collaborators
Mahidol University
Principal Investigator: Julajak Limsrivilai, MD Mahidol University
  More Information

Responsible Party: Mahidol University Identifier: NCT01753128     History of Changes
Other Study ID Numbers: 334/2553 (EC3)
Study First Received: December 17, 2012
Last Updated: August 15, 2014

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs processed this record on September 21, 2017